TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05918874

Intervention type: OTHER
Intervention: Descriptive questionnaire
Description: Questionnaires were administered to calculate whether the children were obese or not, to determine their asthma control levels, to determine their physical activity levels and to determine their leisure time activities.

Intervention type: OTHER
Intervention: Descriptive questionnaire
Description: Questionnaires were administered to calculate whether the children were obese or not, to determine their asthma control levels, to determine their physical activity levels and to determine their leisure time activities.
Study: NCT04800302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continous Quadratum Lumborum Block III
Description: Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum \& psoas major muscles with ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single dose Quadratum Lumborum Block III
Description: Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single dose Quadratum Lumborum Block III
Description: Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-venous Morphine
Description: Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-venous Morphine
Description: Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-venous Morphine
Description: Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
Study: NCT05599724

Intervention type: OTHER
Intervention: Biocollection
Description: For the FERTITHEQUE, will be collected:~* Clinical characteristics~* Biological characteristics measured as part of the usual follow-up~* consultation n°2 : DNA~* consultation n°2 : plasma~* consultation n°2 : serum~* consultation n°2 : vaginal microbiota~* consultation n°3 : follicular fluid (puncture fluid)~* consultation n°4 : plasma~* consultation n°4 : vaginal microbiota.
Study: NCT05538247

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin
Description: Immediate release oral capsules 50 mg, 3 times a day for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Immediate release oral capsules 50 mg, 3 times a day for 6 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S. boulardii CNCM I-745
Description: Two 250 mg capsules orally twice daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two 250 mg capsules that contains no active study ingredient orally twice daily for 14 days
Study: NCT05304026

Intervention type: DEVICE
Intervention: Technique 1
Description: It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F pigtail catheter placed at the level of renal arteries to identify the lowest renal artery.

Intervention type: DEVICE
Intervention: Technique 2
Description: It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F introducer placed at the end of the proximal sealing zone to identify the lowest renal artery.

Intervention type: DEVICE
Intervention: Technique 3
Description: It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F pigtail catheter through the pigtail catheter placed at the level of renal arteries.

Intervention type: DEVICE
Intervention: Technique 4
Description: It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F introducer placed at the level of the contralateral iliac limb.
Study: NCT05540379

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Training
Description: Training the obstetrics and Gynecologist Residents on Virtual endoscopic simulation and skills acquisition

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Training
Description: Training the obstetrics and Gynecologist Residents on Virtual endoscopic simulation and skills acquisition
Study: NCT06052020

Intervention type: DRUG
Intervention: Alirocumab
Description: alirocumab (75 mg every 2 weeks)

Intervention type: DRUG
Intervention: Atorvastatin
Description: Atorvastatin 20-40mg
Study: NCT06401967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivot Clear
Description: A mobile app and program for alcohol reduction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BACtrack breathalyzer
Description: Personal breathalyzer device that measures blood alcohol content.
Study: NCT00867841

Intervention type: PROCEDURE
Intervention: nasopharyngeal swab
Description: PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
Study: NCT04965857

Intervention type: DIAGNOSTIC_TEST
Intervention: Hologic's Genius Digital Diagnostics System
Description: Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
Study: NCT05558761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline 400 MG
Description: Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics. PTX exerts anti-inflammatory effects by inhibiting phosphodiesterase and activating the adenosine 2 receptor
Study: NCT04955366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belatacept
Description: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept is an immunosuppressive medication and will be given SQ at a dose of 125 mg s.c. weekly
Study: NCT06570304

Intervention type: PROCEDURE
Intervention: iCount Device
Description: Designed as single use. Intended purpose - To be used to count swabs and tampons after surgery in an objective manner. This is intended to be used in patients during and just after surgery.~This is a device accessory.
Study: NCT04689568

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moodkit
Description: MoodKit is divided into four main sections: Activities, Thoughts, Mood and Journal. In the Thoughts section, the user is asked to briefly describe stressful situations and their reactions to the event and is later educated on a number of thought distortions. In the Mood section, the user is asked to give an overall rating of mood, which can be done several times per day. In the Journal section, the user can write freestanding journal entries. Additional areas of advice and goal setting are contained in a section called Thrive Tips.
Study: NCT04328389

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: electric toothbrush
Description: Participants will be instructed to use their electric toothbrushes twice a day for controlling oral plaque

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Professional oral hygiene
Description: Professional oral hygiene using ultrosound scaling and root planing
Study: NCT04629430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-biotic foods/drinks
Description: 2 servings per day
Study: NCT05745714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral/intravenous
Study: NCT04689568

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moodgym
Description: The program consists of five modules each taking 20- to 40-minutes to complete, which are completed in a prescribed order.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: University of Michigan Depression Center Toolkit
Description: The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey.
Study: NCT04855513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is a medication used for treatment of diabetes. In this study it will be used to explore is potential role in prevention of preeclampsia. The drug will start before 12 week of pregnancy and continue till delivery
Study: NCT06229717

Intervention type: DIAGNOSTIC_TEST
Intervention: video Head Impulse Test
Description: For v-HIT, the Synapsys v-HIT Ulmer device is used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cervical Vestibular Evoked Myogenic Potential
Description: For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Vestibular Evoked Myogenic Potential
Description: For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized Dynamic Posturography
Description: To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.

Intervention type: OTHER
Intervention: Dizziness Handicap Inventory for patient caregivers
Description: DHI is a caregiver-reported 21- item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
Study: NCT05745714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal chemotherapy
Description: IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
Study: NCT06357923

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: dosage
Description: Presence of mutation on the gene panel and Frequency of allele variation
Study: NCT06109194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint mobilization
Description: Grade III manual joint mobilization as standard-of-care physical therapy intervention
Study: NCT04826003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7122290
Description: RO7122290 will be administered using a QW (Part I) or Q3W (Part I or Part II) schedule in combination with 100 mg cibisatamab Q3W with obinutuzumab pre-treatment. The maximum dose of RO7122290 to be explored in combination with cibisatamab with obinutuzumab pre-treatment in this study is 500 mg for the QW dosing interval (Part I) or 1500 mg for the Q3W dosing interval (Part I or Part II).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7122290
Description: RO7122290 will be administered using a QW (Part I) or Q3W (Part I or Part II) schedule in combination with 100 mg cibisatamab Q3W with obinutuzumab pre-treatment. The maximum dose of RO7122290 to be explored in combination with cibisatamab with obinutuzumab pre-treatment in this study is 500 mg for the QW dosing interval (Part I) or 1500 mg for the Q3W dosing interval (Part I or Part II).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cibisatamab
Description: Cibisatamab will be administered to participants at a fixed dose of 100 mg Q3W (100 mg on Day 1 of each 21-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cibisatamab
Description: Cibisatamab will be administered to participants at a fixed dose of 100 mg Q3W (100 mg on Day 1 of each 21-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered (IV) as pre-treatment on Day - 8/- 7 (split dose) or~- 8 (single dose) prior to C1D1 of cibisatamab and as re-treatment every 6 months if the participant is still receiving cibisatamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered (IV) as pre-treatment on Day - 8/- 7 (split dose) or~- 8 (single dose) prior to C1D1 of cibisatamab and as re-treatment every 6 months if the participant is still receiving cibisatamab
Study: NCT04709783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-Step Workout for Life
Description: Participants will receive the modified 3-step Workout for Life program given by their physical therapy or occupational therapy providers. The program includes single-joint and multiple joint progressive resistance exercise and activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and/or lower extremity. During the activities of daily living exercise, participants will practice activities of daily living that they experience difficulty. The intervention volume, duration, and frequency will be modified to enhance practicality in a home health care setting over the implementation phase. In addition to the 3-Step Workout for Life exercise, participants may also receive other routine rehabilitation treatment determined and provided by their therapists to facilitate their functional recovery.
Study: NCT05386095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0.25%Bupivacaine Axillary brachial plexus block
Description: Axillary brachial plexus block will be induced with patient in supine position under GA with the linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle .The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.25% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.19% Bupivacaine Axillary brachial plexus block
Description: Axillary brachial plexus block will be induced with patient in supine position under GA with linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle.The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.19% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
Study: NCT05960032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: Participants receiving single dose of Zavegepant 10 mg
Study: NCT05300464

Intervention type: DEVICE
Group type: OTHER
Intervention: Clinical investigation medical device class IIa marked CE
Description: Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients are ready for MammoWave exam. The exam will composed of two phases: the acquisition and data processing. During the acquisition that sholud takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
Study: NCT04692181

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SYN-004, Ribaxamase or Placebo
Description: SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SYN-004, Ribaxamase or Placebo
Description: SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SYN-004, Ribaxamase or Placebo
Description: SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SYN-004, Ribaxamase or Placebo
Description: SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SYN-004, Ribaxamase or Placebo
Description: SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SYN-004, Ribaxamase or Placebo
Description: SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines
Study: NCT04680260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients will be offered adjuvant chemotherapy according to standard of care. Follow up will be performed with imaging according to standard guidelines, equal to the experimental arm. Blood samples will be analyzed retrospectively to evaluate the ctDNA status.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA guided treatment approach
Description: Circulating tumor-marker positivity will lead to escalation with 6 months of intensified chemotherapy consisting of 4 months of FOLFOXIRI followed by 2 months of 5FU monotherapy. Circulating tumor-marker negativity will based on shared decision-making lead to de-escalation i.e. possibilities for observation in patients otherwise eligible for monotherapy or observation/monotherapy in patients, otherwise eligible for combination chemotherapy according to standard of care.
Study: NCT05747313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Phase Ib:~The dose of vincristine administered in this phase is 40 mg on days 1,3,5 of each cycle.~The timepoint for chidamide dosing in this phase is twice weekly, i.e., dosing on days 1,4,8,11,15,18 of each cycle. Take 30 minutes after a meal.~Phase II:~This phase is based on the MTD/RP2D determined in phase I. The phase II expansion group study was conducted. Vincristine is administered at a dose of 40 mg on days 1,3,5 of each cycle. Chidamide was administered at a dose of MTD/RP2D twice a week on days 1,4,8,11,15 and 18 of each cycle. It is to be taken 30 minutes after a meal.
Study: NCT05377346

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placement of the i-gel
Description: The lubricated i-gel is inserted into the mouth and introduced along the hard palate with a continuous and gentle push until resistance was felt in the hypopharynx.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placement of the i-gel
Description: The lubricated i-gel is inserted into the mouth and introduced along the hard palate with a continuous and gentle push until resistance was felt in the hypopharynx.
Study: NCT06536517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)

Intervention type: DRUG
Group type: OTHER
Intervention: Methadone
Description: Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)
Study: NCT06429852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The DeST-ACT Trauma-Focused Acceptance and Commitment Therapy Program
Description: The Trauma-focused psychosocial intervention program consists of 4 sessions online therapy.